I saw this news report and I am posting for others see. It came out today. Title: Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma — No PFS benefit from adding the monoclonal antibody to standard therapy https://www.medpagetoday.com/hematologyoncology/myeloma/108823?xid=nl_mpt_DHE_2024-02-20&eun=g2146371d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Evening%202024-02-20&utm_term=NL_Daily_DHE_dual-gmail-definition